Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Evolva SA | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Previous research shows that a diet high in fat has harmful effects on gut health. This increases the chance of developing obesity-related diseases (such as type 2 diabetes) and disrupts cognition and mood.
Research has suggested that gut health can be improved by taking certain supplements, including resveratrol (a polyphenol found primarily in red grape skins). Resveratrol has also been shown to improve brain blood flow and possibly brain function - however, there is limited research studying this.
This study will investigate the effects of 12 weeks daily consumption of resveratrol on cognitive function, cerebral blood flow, gut microbiota and systemic inflammation in overweight and obese healthy adults.
Each participant will be required to attend the laboratory on four occasions. The first of these will be an initial screening/training visit, this will take place in the afternoon and last 3 hours in total. During the initial visit participants will be asked to provide written informed consent. They will provide lifestyle and demographic data and screened regards to physical health (height, weight, blood pressure, waist to hip ratio). They will then be trained on the computerised cognitive and mood tasks. At the end of the appointment they will be provided with a food diary and a stool sample collection kit.
Study days 1 and 2 (12 weeks apart) :
Participants will arrive at the laboratory at 8.00am having fasted from 8pm the previous evening, avoided caffeinated products for 18 hours, alcohol and over the counter medication for 24 hours and oral antihistamines for 48 hours prior to the session commencing. They will also bring with them their completed food diary and stool sample.
Participants will provide a blood sample and then will be given a standardised breakfast of x2 slices of white toast with butter and a decaf tea or coffee. They will also provide a urine sample. Participants will then complete a computerised cognitive assessment (~1 hour in length), followed by measurements of blood pressure and heart rate. Participants in the sub-sample who will also provide brain (cerebral) blood flow data, will then have the quantitative near-infrared spectroscopy (qNIRS) headband fitted across the forehead and a 5 minute baseline measure will be recorded.
Following this the participants will consume their treatment for the day, followed by a short break and then will complete the second cognitive assessment. The qNIRS participants will again provide brain blood flow data and following that will be provided with a standardised lunch (cheese sandwich, ready salted crisps and a custard pot). Participants will complete their final cognitive assessment and will then provide a second blood sample.
At the end of the first study day participants will be provided with their treatment and treatment diary, they will be instructed to take one tablet twice a day (with breakfast and dinner). Both study days will be identical and will take place 84 days (+/- 5 days) apart.
Participants are also required to attend a short treatment exchange visit during Week 6 (5 minutes).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Resveratrol | Experimental | 500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day). |
|
| Placebo | Placebo Comparator | Matched placebo capsules (1 capsule consumed at two timepoints each day). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Resveratrol | Dietary Supplement | Participants will consume one of the treatment types daily for a period of three months. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline cognitive (memory) performance at 45 minutes, 240 minutes and 12 weeks post dose | Memory performance will be assessed using a computerised cognitive battery (administered using COMPASS cognitive assessment program). Memory will be assessed using 3 global measures (Working memory, speed of memory and episodic memory). The global measures are created by taking data from several tasks targeting that cognitive domain. Working memory: a combined accuracy score (% correct) from the tasks: numeric working memory (NWM), serial 3's subtractions (SS3), serial 7's subtractions (SS7) and rapid visual information processing (RVIP). Speed of memory: a combined speed score (msecs) from tasks NWM, delayed name to face recall, delayed picture recognition and delayed word recognition. Episodic memory: a combined accuracy score (% correct) from tasks immediate word recall, delayed word recall, delayed name to face recall, delayed picture recognition, delayed word recognition. | 45 minutes, 240 minutes, 12 weeks |
| Change from baseline cognitive (Attention) performance at 45 minutes, 240 minutes and 12 weeks post dose | Attention performance will be assessed using a computerised cognitive battery (administered using COMPASS cognitive assessment program). Attention will be assessed using 2 global measures (Accuracy of Attention and Speed of Attention). Accuracy of Attention: accuracy score (% correct) from choice reaction time task. Speed of attention: speed score (msecs) taken from choice reaction time task. | 45 minutes, 240 minutes, 12 weeks |
| Gut microbiota | Changes in gut microbiota communities, quantified using 16S ribosomal ribonucleic acid (rRNA) gene community analysis. | 12 weeks |
| Change from baseline systemic inflammatory cytokines | Inflammatory cytokines (including C-reactive protein and Interleukin-6) will be measured in plasma using ELISA analysis, in association with other endpoints including resveratrol metabolites. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline Blood Pressure | Systolic and diastolic blood pressure will be taken after each cognitive assessment (measured in mm Hg). | 45 minutes, 240 minutes, 12 weeks |
| Change from baseline Heart Rate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
You should not take part if you:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Emma Wightman, Dr | Northumbria University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Northumbria University | Newcastle upon Tyne | Tyne and Wear | NE1 8ST | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants will recieve either Resveratrol or Placebo for a period of 3 months.
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | Participants will consume one of the treatment types daily for a period of three months. |
|
| 5 hours, 12 weeks |
| Change from baseline urinary and plasma metabolome | Changes in plasma and urinary metabolome will be profiled using a Thermo Q-Exactive liquid chromatography/mass spectrometry spectrometer and data analysed using Progenesis QI. | 12 weeks |
| Change from baseline total haemoglobin cerebral blood flow (CBF) measurement | CBF of the frontal cortex measured using quantitative near infrared spectroscopy (q-NIRS). | 115-190 minutes, 12 weeks |
| Change from baseline deoxygenated haemoglobin CBF measurement | CBF of the frontal cortex measured using qNIRS. | 115-190 minutes, 12 weeks |
| Change from baseline oxygen saturation CBF measurement | CBF of the frontal cortex measured using qNIRS. | 115-190 minutes, 12 weeks |
Heart rate will be measured after each cognitive assessment (measured in BPM).
| 45 minutes, 240 minutes, 12 weeks |
| Change from baseline subjective mood score | Subjective mood scores will be measured using the Profile of Mood scale. The questionnaire includes 65 items and participants rate their mood on a scale of 0-4 (not at all - extremely). These scores are collapsed into 6 mood outcomes (Tension, depression, anger, vigour, fatigue and confusion) and a total mood disturbance score. | 240 minutes, 12 weeks |
| Weight change and BMI | Change in weight and BMI between visits | 12 weeks |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077185 | Resveratrol |
| ID | Term |
|---|---|
| D000081225 | Stilbestrols |
| D013267 | Stilbenes |
| D001597 | Benzylidene Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D059808 | Polyphenols |
| D010636 | Phenols |
Not provided
Not provided